Celldex Therapeutics (CLDX) Cash from Investing Activities (2010 - 2026)

Celldex Therapeutics' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at $72.1 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 67.91% year-over-year to $72.1 million; the TTM figure through Mar 2026 stood at $238.2 million (up 250.19% YoY), while the FY2025 annual figure was $209.1 million, up 172.06% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $72.1 million, up from $55.4 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $72.1 million in Q1 2026, with the low at -$315.2 million in Q1 2024.
• The 5-year median for Cash from Investing Activities is $25.3 million (2022), against an average of -$1.5 million.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities jumped 406.45% in 2023, then slumped 4114.0% in 2024.
• Celldex Therapeutics' Cash from Investing Activities stood at $31.2 million in 2022, then plunged by 648.36% to -$171.2 million in 2023, then soared by 114.05% to $24.0 million in 2024, then soared by 130.49% to $55.4 million in 2025, then surged by 30.12% to $72.1 million in 2026.
• Business Quant data shows CLDX's Cash from Investing Activities at $72.1 million in Q1 2026, $55.4 million in Q4 2025, and $60.8 million in Q3 2025.